These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
604 related articles for article (PubMed ID: 10482368)
1. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease. Yamano Y; Takamatsu J; Sakane S; Hirai K; Kuma K; Ohsawa N Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368 [TBL] [Abstract][Full Text] [Related]
2. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects. Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248 [TBL] [Abstract][Full Text] [Related]
3. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease. Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459 [TBL] [Abstract][Full Text] [Related]
4. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment. Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255 [TBL] [Abstract][Full Text] [Related]
5. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease. Shibayama K; Ohyama Y; Yokota Y; Ohtsu S; Takubo N; Matsuura N Endocr J; 2005 Oct; 52(5):505-10. PubMed ID: 16284425 [TBL] [Abstract][Full Text] [Related]
6. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Maugendre D; Massart C Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931 [TBL] [Abstract][Full Text] [Related]
7. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease. Choo YK; Yoo WS; Kim DW; Chung HK Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556 [TBL] [Abstract][Full Text] [Related]
8. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report. Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094 [TBL] [Abstract][Full Text] [Related]
9. Blocking-type anti-TSH receptor antibodies and relation to responsiveness to antithyroid drug therapy and remission in Graves' disease. Tada H; Mizuta I; Takano T; Tatsumi KI; Izumi Y; Hidaka Y; Amino N Clin Endocrinol (Oxf); 2003 Apr; 58(4):403-8. PubMed ID: 12641621 [TBL] [Abstract][Full Text] [Related]
10. Interactions between TSH binding inhibiting--and adenylate cyclase stimulating--antibodies in Graves' disease. Morita S; Izumi M; Nagataki S Acta Endocrinol (Copenh); 1986 Aug; 112(4):517-22. PubMed ID: 2875588 [TBL] [Abstract][Full Text] [Related]
11. Assays of TSH-receptor antibodies in 576 patients with various thyroid disorders: their incidence, significance and clinical usefulness. Macchia E; Concetti R; Borgoni F; Cetani F; Fenzi GF; Pinchera A Autoimmunity; 1989; 3(2):103-12. PubMed ID: 2577491 [TBL] [Abstract][Full Text] [Related]
12. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment. Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869 [TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of Graves' immunoglobulin G: comparison of thyrotropin receptor antibodies in serum and in culture supernatants of lymphocytes transformed by Epstein-Barr virus infection. Yokoyama N; Izumi M; Katamine S; Nagataki S J Clin Endocrinol Metab; 1987 Feb; 64(2):215-8. PubMed ID: 2878934 [TBL] [Abstract][Full Text] [Related]
14. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease]. Chen W; Man N; Li YS; Shan ZY; Teng WP Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113 [TBL] [Abstract][Full Text] [Related]
15. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment. Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228 [TBL] [Abstract][Full Text] [Related]
16. Methodological aspects and clinical results of an assay for thyroid-stimulating antibodies: correlation with thyrotropin binding-inhibiting antibodies. Hensen J; Kotulla P; Finke R; Bogner U; Badenhoop K; Meinhold H; Schleusener H J Clin Endocrinol Metab; 1984 Jun; 58(6):980-7. PubMed ID: 6144692 [TBL] [Abstract][Full Text] [Related]
17. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. McLachlan SM; Rapoport B Thyroid; 2013 Jan; 23(1):14-24. PubMed ID: 23025526 [TBL] [Abstract][Full Text] [Related]
18. Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study. Teng CS; Yeung RT J Clin Endocrinol Metab; 1980 Jan; 50(1):144-7. PubMed ID: 6892512 [TBL] [Abstract][Full Text] [Related]
19. Use of cells expressing the human thyrotropin (TSH) receptor for the measurement of thyroid stimulating and TSH-blocking antibodies. Vitti P; Chiovato L; Fiore E; Mammoli C; Rocchi R; Pinchera A Acta Med Austriaca; 1996; 23(1-2):52-6. PubMed ID: 8767515 [TBL] [Abstract][Full Text] [Related]
20. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]